Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 6/20 | 0.48 |
| ▸ | PPARG | P37231 | 3/20 | 0.48 |
| ▸ | PPARD | Q03181 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6813922 | 0.88 | PPARA (0.53) | PPARAPPARGPPARDALDH1A1ACACB | |
| SCHEMBL6817914 | 0.87 | FFAR1 (0.47) | PPARAPPARGPPARDMAOBFFAR1 | |
| SCHEMBL6818157 | 0.87 | PPARA (0.52) | PPARAPPARGPPARDALDH1A1MAPT | |
| SCHEMBL6814654 | 0.81 | PPARA (0.71) | PPARAPPARGPPARDFFAR1LMNA | |
| SCHEMBL5991976 | 0.80 | PPARA (0.56) | PPARAPPARGPPARDALDH1A1MAPT | |
| SCHEMBL4026049 | 0.76 | PPARG (0.50) | PPARAPPARGPPARDLMNA | |
| SCHEMBL6817531 | 0.74 | PPARA (0.53) | PPARAPPARG | |
| SCHEMBL6813874 | 0.74 | PPARA (0.53) | PPARAPPARG | |
| SCHEMBL6813690 | 0.74 | PPARA (0.53) | PPARAPPARG | |
| SCHEMBL5831258 | 0.73 | LDHA (0.50) | PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1237857-B1 | NEW PHENALKYLOXY-PHENYL DERIVATIVES | ASTRAZENECA AB (SE) | 2004-06-30 | — | — | EP | claimed |
| US-6630509-B2 | Pharmaceutical medication associated with insulin resistance; patient with prophylaxis conditions having reduced sensitivity to insulin | ASTRAZENECA AB (SE) | 2003-10-07 | — | — | US | claimed |
| US-20090275565-A1 | Substituted aralkyl derivatives | CADILA HEALTHCARE LIMITED (IN) | 2009-11-05 | — | — | US | disclosed |
| EP-1569916-B1 | SUBSTITUTED ARALKYL DERIVATIVES | CADILA HEALTHCARE LTD (IN) | 2009-01-07 | — | — | EP | disclosed |
| EP-1237857-B1 | NEW PHENALKYLOXY-PHENYL DERIVATIVES | ASTRAZENECA AB (SE) | 2004-06-30 | — | — | EP | disclosed |
| EP-1237857-A1 | NEW PHENALKYLOXY-PHENYL DERIVATIVES | AstraZeneca AB (SE) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001040170-A1 | NEW PHENALKYLOXY-PHENYL DERIVATIVES | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275565-A1 | Substituted aralkyl derivatives | UGT1A7, UGT1A10, UGT2B7 | PPARA 2339/4885PPARG 2043/4885PPARD 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.